Loading financials from SEC filings…
Specialty chemicals · Basic Materials · Fiscal year ends Dec 31
Sensient Technologies reported revenue of $1.6B in the fiscal year ended Dec 2025, up 3.5% from the year before. Operating income was $207M, an operating margin of 12.8%, and net income was $134M. Operating cash flow of $128M less capital expenditure of $89M left free cash flow of $38M. Net debt was $673M.
Ranks among the 20 specialty chemicals companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1,380 | 1,437 | 1,456 | 1,557 | 1,612 |
| Cost of revenue | 926 | 948 | 996 | 1,050 | 1,073 |
| Gross profit | 455 | 489 | 460 | 507 | 539 |
| Research & development | 34.3 | 42.2 | 48.1 | 49.1 | 52.9 |
| Selling, general & admin | 285 | 292 | 305 | 316 | 332 |
| Operating income | 170 | 197 | 155 | 192 | 207 |
| Interest expense | 12.5 | 14.5 | 25.2 | 28.8 | 29.6 |
| Pre-tax income | 157 | 182 | 130 | 163 | 178 |
| Income tax | 38.7 | 41.3 | 36.5 | 38.1 | 43.1 |
| Net income | 119 | 141 | 93.4 | 125 | 134 |
| Diluted EPS | 2.81 | 3.34 | 2.21 | 2.94 | 3.16 |
| Diluted shares | 42.3 | 42.2 | 42.2 | 42.4 | 42.6 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 25.7 | 20.9 | 28.9 | 26.6 | 36.5 |
| Receivables | 261 | 302 | 272 | 290 | 305 |
| Inventory | 412 | 564 | 598 | 600 | 678 |
| Current assets | 741 | 935 | 937 | 962 | 1,081 |
| Net PP&E | 446 | 483 | 505 | 492 | 539 |
| Goodwill | 420 | 416 | 424 | 412 | 440 |
| Total assets | 1,745 | 1,982 | 2,015 | 2,024 | 2,244 |
| Payables | 126 | 142 | 131 | 139 | 138 |
| Current liabilities | 232 | 272 | 236 | 271 | 264 |
| Short-term debt | 0.5 | 0.5 | 0.1 | 0.2 | 0.2 |
| Long-term debt | 503 | 630 | 645 | 614 | 709 |
| Total liabilities | 807 | 982 | 961 | 963 | 1,051 |
| Shareholders' equity | 938 | 1,000 | 1,053 | 1,061 | 1,194 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | 145 | 12.1 | 170 | 157 | 128 |
| Capital expenditure | 60.8 | 79.3 | 87.9 | 59.2 | 89.4 |
| Free cash flow | 84.4 | −67.3 | 81.8 | 97.9 | 38.4 |
| Depreciation & amortisation | 52.1 | 52.5 | 57.8 | 60.3 | 61.1 |
| Stock-based compensation | 9.6 | 16.1 | 8.9 | 10.1 | 13.9 |
| Share buybacks | 42.5 | 0.0 | 0.0 | – | – |
| Dividends paid | 66.7 | 68.9 | 69.2 | 69.4 | 69.6 |
| Dividend per share | 1.58 | 1.64 | 1.64 | 1.64 | 1.64 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 4.1% | 1.4% | 6.9% | 3.5% |
| Operating income growth (YoY) | – | 15.7% | −21.2% | 23.6% | 8.1% |
| EPS growth (YoY) | – | 18.9% | −33.8% | 33.0% | 7.5% |
| Gross margin | 32.9% | 34.0% | 31.6% | 32.6% | 33.5% |
| Operating margin | 12.3% | 13.7% | 10.6% | 12.3% | 12.8% |
| Net margin | 8.6% | 9.8% | 6.4% | 8.0% | 8.3% |
| Return on equityBlank when equity is negative | 12.7% | 14.1% | 8.9% | 11.8% | 11.3% |
| ROCEEBIT ÷ (assets − current liabilities) | 11.2% | 11.5% | 8.7% | 10.9% | 10.5% |
| Free cash flow margin | 6.1% | −4.7% | 5.6% | 6.3% | 2.4% |
| Cash conversion (CFO ÷ net income) | 1.22x | 0.09x | 1.82x | 1.26x | 0.95x |
| Receivable days | 69 | 77 | 68 | 68 | 69 |
| Inventory days | 162 | 217 | 219 | 209 | 231 |
| Payable days | 49 | 55 | 48 | 48 | 47 |
| Interest cover | 13.6x | 13.5x | 6.16x | 6.66x | 7.00x |
| Debt ÷ equity | 0.54x | 0.63x | 0.61x | 0.58x | 0.59x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | 478 | 610 | 616 | 587 | 673 |
| Current ratio | 3.19x | 3.43x | 3.96x | 3.55x | 4.10x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.